Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 7, 1997, Pages 507-511

  Beovic B ^a   Lejko Zupanc, T ^a   Pretnar, J ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; CREATININE; LIVER ENZYME;

ADULT; AGED; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FEVER; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MALE; METABOLIC ACIDOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RASH; RIGOR; TREATMENT OUTCOME;

ACIDOSIS; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CREATININE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOKALEMIA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030792397     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01708233     Document Type: Article

References (20)

1. Rex JH, Bennett JE, Sugar AM, Pappas PG, van den Horst CM, Edwards JE, Washburn RG, Scheid WM, Karchmer AW, Dine AP, Levenstein MJ, Webb D, for the Candidaemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 1994, 331: 1325-1330.
2. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, Potts D, Shelton M, Sugar A: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B treatment. American Journal of Medicine 1991, 91: 142-150.
3. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40-44.
4. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 1-8.
5. Johnson EM, Warnock DW: Azole drug resistance in yeast. Journal of Antimicrobial Chemotherapy 1995, 36: 751-755.
6. Khoo SH, Bond J, Denning DW: Administering amphotericin B - a practical approach. Journal of Antimicrobial Chemotherapy 1994, 33: 203-213.
7. Guo LSS, Fielding RM, Lasic DD: Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulphate discs. International Journal of Pharmacokinetics 1991, 75: 45-59.
8. Fromtling RA: Amphotericin B cholesterol sulfate complex. Drugs of the Future 1993, 18: 303-306.
9. DeMarie S, Janknegt R, Bakker-Woudenberg IAJM: Clinical use of liposomal and lipid complexed amphotericin B. Journal of Antimicrobial Chemotherapy 1994, 33: 907-916.
10. Mills W, Chopra R, Linch DC, Goldstone AH: Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single center experience of 133 episodes in 116 patients. British Journal of Hematology 1994, 86: 754-760.
11. Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J: Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation 1994, 14, Supplement 5: 10-14.
12. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clinical Infectious Diseases 1992, 15: 414-421.
13. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Archives of Internal Medicine 1988, 148: 2642-2645.
14. Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clinical Infectious Diseases 1995, 21: 1145-1153.
15. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Journal of Infectious Diseases 1996, 173: 1208-1215.
16. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL: Risk factors for amphotericin B associated nephrotoxicity. American Journal of Medicine 1989, 87: 547-552.
17. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD: Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrobial Agents and Chemotherapy 1995, 39: 2042-2047.
18. Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, Fonschiffrey G, Ksionski G, Dember J: Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Transactions of the Royal Society of Tropical Medicine and Hygiene 1995, 89: 309-311.
19. Meunier F: Candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 438-447.
20. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 1990, 12: 308-329.